Evidence map›Paper›PMID 39539387›Full record

ArticleAdvanced functional materials2024

Phosphatidylserine-incorporated exosome mimetics encapsulating CXCR3 antagonist alleviate osteoporosis.

Minjee Kang, Zhi Li, Insoon Chang, Changlu Xu, Michelle Chiang, Lauren Kim, Yutong Wu, Jiabing Fan, Tara L Aghaloo, Min Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Extracellular Vesicle Lipids and Their Role in Delivery.Journal of extracellular biology · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minjee KangDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Zhi LiDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Insoon ChangDivision of Regenerative and Reconstructive Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Changlu XuDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Michelle ChiangDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Lauren KimDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Yutong WuDepartment of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jiabing FanDepartment of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, Maryland 21853, USA.
Tara L AghalooDivision of Diagnostic and Surgical Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Min LeeDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.

Funding

Tribbles homolog 3 and BMP-2 induced bone formationR01DE027332 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tara L Aghaloo, Min Lee · 2018 to 2026
$2.7M
Hydrogel delivery of DBM and exosome mimetics for bone repairR01DE031711 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Min Lee · 2022 to 2026
$1.8M
NIDCR NIH HHS R01 DE027332NIDCR NIH HHS R01 DE031711
6 · The paper itself

Abstract

Exosomes derived from mesenchymal stem cells are an active area of research due to their therapeutic potential in treating osteoporosis. To further harness their therapeutic performance in modulating bone resorption, we have equipped exosomes with osteoclast-targeting moieties on their surface as well as chemokine receptor antagonists blocking osteoclast recruitment. Phosphatidylserine (PS), a membrane lipid exerting immunosuppressive and phagocytic signals, was incorporated in the membrane of exosome mimetics (EMs) to achieve a marked affinity for osteoclast precursors and potential anti-resorptive effects. We also aimed to tackle a CXCL9-CXCR3 ligand-receptor axis, a critical signaling axis in regulating osteoclast precursor recruitment and differentiation at bone resorption sites, by encapsulating a chemical antagonist of CXCR3, AMG487, in the PS-incorporated EMs (PS-EMs). The osteoclast-targeting PS-EMs loaded with AMG487 effectively protected against bone loss in an ovariectomized mouse model. Our findings demonstrate the great promise of PS-EMs as anti-resorptive nanotherapies for alleviating osteoporosis.

Indexed as

Drug delivery systemsExosome-mimeticsExosomesExtracellular vesiclesOsteoporosis

Identifiers

PMID39539387
PMCPMC11556507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.